

## Discrimination of SARS-Cov 2 and arboviruses (DENV, ZIKV and CHIKV) clinical features using machine learning techniques: a fast and inexpensive clinical screening for countries simultaneously affected by both diseases

João Daniel S. Castro<sup>a, b\*</sup>

[joaodasc@gmail.com](mailto:joaodasc@gmail.com)

<sup>a</sup> Universidade do Estado da Bahia, Departamento de Ciências Exatas e da Terra, Programa de Pós-Graduação em Química Aplicada, Salvador, BA, Brazil,

<sup>b</sup> Secretária da Educação do Estado da Bahia, Centro Administrativo da Bahia - CAB, Salvador, BA, Brazil

### Abstract

SARS-Cov-2 (Covid-19) has spread rapidly throughout the world, and especially in tropical countries already affected by outbreaks of arboviruses, such as Dengue, Zika and Chikungunya, and may lead these locations to a collapse of health systems. Thus, the present work aims to develop a methodology using a machine learning algorithm (Support Vector Machine) for the prediction and discrimination of patients affected by Covid-19 and arboviruses (DENV, ZIKV and CHIKV). Clinical data from 204 patients with both Covid-19 and arboviruses obtained from 23 scientific articles and 1 dataset were used. The developed model was able to predict 93.1% of Covid-19 cases and 82.1% of arbovirus cases, with an accuracy of 89.1% and Area under Roc Curve of 95.6%, proving to be effective in prediction and possible screening of these patients, especially those affected by Covid-19, allowing early isolation.

Keywords: Coronavirus; Covid-19; Arbovirus; Machine Learning; Clinical Features; Dengue; Zika; Chikungunya

### Introduction

- 1 In December 2019, a series of pneumonia cases of unknown cause emerged among
- 2 visitors to a wet market in the city of Wuhan, Hubei (China). Genetic sequencing of
- 3 samples from the respiratory tract of these patients identified a new type of Coronavirus,

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

4 called (2019-nCoV) [1], which since the outbreak, has affected more than 1 million  
5 people and totals 60,000 deaths worldwide [2,3].

6 Covid-19 produces a systemic respiratory disease that can progress to severe pneumonia  
7 in approximately 16% of cases [4]. Sepsis is the most frequent complication, followed by  
8 respiratory failure, acute respiratory distress (ARDS), heart failure and septic shock [5].

9 Concomitantly with the Covid-19 outbreak, tropical countries have faced successive  
10 outbreaks of arboviruses, such as Dengue (DENV), Zika (ZIKV) and Chikungunya  
11 (CHIKV), presenting themselves as a challenge to the health systems of these countries.  
12 Arboviruses are diseases caused by viruses transmitted to humans through the bites of  
13 infected blood-sucking arthropods, predominantly *Aedes* mosquitoes [6], and their  
14 clinical manifestations can vary from mild and undifferentiated febrile disease to  
15 neurological, joint and hemorrhagic febrile syndromes [7]. In addition, it is observed that  
16 there is a low probability of predicting a possible outbreak [8], which may surprise health  
17 systems that, today, are saturated due to the Covid-19 pandemic.

18 The imminence of a syndemic state between Covid-19 and arboviruses (mainly Dengue)  
19 has been shown to be a concern of researchers from Latin American countries [9,10].  
20 Even though it has not yet reported cases of co-infection, your treatment may be adversely  
21 affected, since the spectrum of drugs does not seem compatible [11]. Associated with this,  
22 researchers have reported a false positive diagnosis for Dengue in situations in which  
23 patients are affected by the SARS-CoV-2 virus [12,13], even though there was no  
24 genomic similarity between the viruses [14], which can make the diagnosis of these  
25 diseases even more difficult.

26 Brazil has historically faced cycles of arbovirus epidemics throughout its territory, with  
27 Dengue being the most prevalent arbovirus [15]. According to the most recent Brazilian  
28 epidemiological bulletin, until now (ie, April 06, 2020) approximately 500 thousand cases  
29 of arboviruses have been reported (DENV, ZIKV, CHIKV), 96% of which are associated  
30 with dengue, 2.73% Chikungunya and 0.33% to Zika [16], compared to 9506 cases of  
31 Covid-19 (until April 3) [17].

32 Thus, in order to optimize resources and care for patients, as well as to enable effective  
33 screening, allowing isolation and early management, biomarkers (obtained through blood  
34 counts at admission) can be effective in predicting the degree of severity of disease.  
35 Studies indicate that Covid-19 causes Lymphocytopenia [4] and Thrombocytopenia [18],

36 while arboviruses can cause Leukopenia, Lymphohistiocytosis and mild  
37 Lymphocytopenia [19–22].

38 Therefore, based on the clinical data of patients affected by Covid-19 or Arboviruses  
39 (DENV, ZIKV and CHIKV), this study aims to build a predictive model using machine  
40 learning algorithms, in order to screen and diagnose patients in case a possible syndemic  
41 state. It is also intended to share clinical data by the medical community about diseases  
42 of global circulation, in order to mitigate their impacts.

43

## 44 2 Materials and Methods

45

46 An electronic search was performed in the databases of Periódicos CAPES (portal of the  
47 Brazilian development agency CAPES, which aggregates numerous publishers of  
48 scientific journals), Google Scholar, Google Dataset and Science Direct, using the  
49 keywords, “Clinical features” OR “ White blood cells count ”OR“ Haemogram ”AND“  
50 coronavirus 2019 ”OR“ COVID-19 ”OR“ 2019-nCoV ”OR“ SARS-CoV-2 ”. To search  
51 for clinical data related to arboviruses, the terms “Clinical features” OR “White blood  
52 cells count” OR “Haemogram” AND “Dengue” OR “Zika” OR “Chikungunya” were  
53 used. A Dataset containing clinical data from Brazilian patients Positive for SARS-CoV-  
54 2 was also added to the data set, made available by Hospital Israelita Albert Einstein [23].

55 The papers were chosen according to the criteria of: analysis of the abstract, title and body  
56 of the text, excluding works that presented only the average of the data obtained for a  
57 group of patients or that did not present the patients' blood count. Thus, 23 scientific  
58 papers were selected, all of which were written in English.

59 This study was carried out in accordance with the Declaration of Helsinki and in  
60 accordance with the terms of local legislation.

61 The predictive model was built using the open-source software Orange (v. 3.20.1) [24].  
62 Before the implementation of the algorithm, the data were normalized (center by mean)  
63 and then submitted to the detection of outliers (abnormal data), using covariance  
64 assessment.

65 The input data for the training of the algorithm were the White Blood Cells count (WBC)  
66 and the Lymphocyte count, available in the articles, and the classes used for the prediction

67 were Covid-19 and Arboviruses. The type of algorithm used was SVM with Cost  
68 regression ( $c = 1.50$ , Kernel type RBF ( $g = 1,04$ ) and the following optimization  
69 parameters: numerical tolerance = 0.005, without iteration limit.

70 The model was trained using the data and validated using the cross-validation  
71 methodology, with  $k$ -fold =20. The validation method consists of dividing the data set  
72 into  $k$  parts, using  $k-1$  parts for modeling (training) and the remaining part for testing. In  
73 this model the data set was tested twenty times, each one with a different fold from  
74 dataset.

75 The idea behind this type of algorithm is to map the data, transposing it into a high  
76 dimensional space in which hyperplanes separate the data into subgroups (clusters)  
77 according to their characteristics, allowing the classification problem to be more easily  
78 solved [25].

79 The model developed is available in supplementary materials.

### 80 3. Results and discussion

81

#### 82 3.1 Characteristics of the included studies

83

84 The detailed characteristics of this study are found in the Dataset available as  
85 supplementary material. Data from 204 patients were used in total, and after detecting  
86 outliers, 120 patients remained positive for SARS-CoV-2 and 67 patients with  
87 arboviruses (DENV, ZIKV and CHIKV), in a wide age group and of both sexes, totaling  
88 187 patients.

89

90 The parameters used for the evaluation and screening was the existence / prevalence of  
91 Leukopenia and Lymphohistiocytosis / Lymphocytopenia, based on what was previously  
92 reported in the literature. Tables 1 and 2 summarize the data found in the literature. It is  
93 worth noting that the dataset provided by Hospital Israelita Albert Einstein [23] was  
94 already normalized, and therefore it is not shown in the data set in the tables below.

95 Table 1. Clinical features of patients affected by Covid-19

| Número de Pacientes | Disease | WBC ( $10^9/L$ ) | Lymphocytes ( $10^9/L$ ) | Observation | Reference |
|---------------------|---------|------------------|--------------------------|-------------|-----------|
|---------------------|---------|------------------|--------------------------|-------------|-----------|

|            |          |                    |                    |              |      |
|------------|----------|--------------------|--------------------|--------------|------|
| 9          | Covid-19 | 7.70 (5.07 -10.61) | 1.18 (0.46-1.59)   | Pregnant     | [26] |
| 5          | Covid-19 | 7.6 (5.03 - 10.76) | 0.74 (0.63 - 0.92) | Hemodialysis | [27] |
| 5          | Covid-19 | 8.75 (6.12 - 12,4) | 1.42 (0.84-2.46)   | Asymptomatic | [28] |
| 5          | Covid-19 | 5.68 (4.4 - 7.1)   | 1.56 (1.3- 1.7)    | Reactivation | [29] |
| 6          | Covid-19 | 6.13 (4.3 – 11.4)  | 1.7 (0.6 – 2.7)    | -            | [30] |
| 4          | Covid-19 | 5.49 (4.23 – 6.84) | 1.19 (0.42 - 1.98) | -            | [31] |
| 2          | Covid-19 | 5.76 (4.37 - 7.16) | 1.03 (0.88 – 1.19) | -            | [32] |
| 1          | Covid-19 | 10.6               | 0.86               | Pregnant     | [33] |
| Total = 37 |          | Mean = 7,06        | Mean = 1,27        |              |      |

96

97 Table 2. Clinical features of patients affected by arboviruses (DENV, ZIKV and CHIKV)

| Número de Pacientes | Disease     | WBC (10 <sup>9</sup> /L) | Lymphocytes (10 <sup>9</sup> /L) | Observation  | Reference |
|---------------------|-------------|--------------------------|----------------------------------|--------------|-----------|
| 1                   | Zika        | 2.28                     | 0.83                             | Liver injury | [34]      |
| 1                   | Zika        | 6.10                     | 1.0                              | -            | [35]      |
| 1                   | Zika        | 4.90                     | 1.42                             | -            | [36]      |
| 12                  | Zika        | 5.96 (3.78 -10.13)       | 2.64 (0.39 – 7.09)               | -            | [37]      |
| 1                   | Zika        | 3.65                     | 0.47                             | -            | [38]      |
| 1                   | Zika        | 3.10                     | 1.55                             | -            | [39]      |
| 1                   | Chikungunya | 3.10                     | 0.7                              | -            | [40]      |
| 14                  | Chikungunya | 7.32 (3.00 -13.00)       | 3.44 (1.30 – 7.54)               | Children     | [41]      |
| 1                   | Chikungunya | 15.7                     | 6.09                             | -            | [42]      |
| 1                   | Chikungunya | 19.1                     | 1.01                             | Erysipelas   | [43]      |
| 3                   | Chikungunya | 28.9 (21.8 -35.1)        | 1.2 (0.7- 1.2)                   | Fatal cases  | [44]      |
| 1                   | Chikungunya | 3.2                      | 1.09                             | -            | [45]      |
| 5                   | Zika/Dengue | 3.65 (1.24 - 6.3)        | 0.96 (0.39 -1.84)                | Coinfection  | [46]      |
| 1                   | Dengue      | 1.60                     | 0.93                             | -            | [47]      |
| 40                  | Dengue      | 7.16 (4.43 - 11.9)       | 4.87 (1.90 - 6.70)               | -            | [48]      |
| Total = 84          |             | Média = 7,48             | Média = 3,55                     |              |           |

98

99 3.2 Model assessment

100

|        |             | Predicted   |            |            |
|--------|-------------|-------------|------------|------------|
|        |             | Arboviruses | Covid -19  | Σ          |
| Actual | Arboviruses | 82.1 %      | 6.9 %      | <b>63</b>  |
|        | Covid -19   | 17.9 %      | 93.1 %     | <b>120</b> |
| Σ      |             | <b>67</b>   | <b>116</b> | <b>183</b> |

101

102 Figure 1. Confusion Matrix for classification test using an SVM machine learning algorithm

103

104 The results of a classification can be represented as a matrix called a confusion matrix, a  
105 square matrix (G x G) whose rows and columns represent the experimental and predicted  
106 data respectively [49].

107 The matrix shows that the model was able to predict more than 90% of Covid-19 cases  
108 and 82.1% of cases of arboviruses, based on clinical data obtained in the literature. The  
109 developed model also has an Area under Roc Curve (AUC) of 0.956, an accuracy of 0.891  
110 and an precision of 0.893.

111 Lymphocytopenia is a clinical condition observed in patients with SARS-CoV-2,  
112 regardless of gender, age and / or pre-existence of comorbidities [50–52].

113 This condition allowed the correct classification of most of the observed cases. The  
114 classification error of individuals affected by arboviruses is also reported by Yan and  
115 collaborators, when describing two clinical pictures of SARS-Cov-2 as false positives for  
116 Dengue (DENV) [12] , showing the urgency in the development of more accurate  
117 methodologies.

118 Leukopenia presents to patients with arboviruses (DENV, ZIKV and CHIKV) in medium  
119 to intense degrees, according to the PAHO (Pan-American Health Organization)  
120 classification [53], and also presented in clinical studies [54,55]. Associated with this,  
121 some patients may experience lymphohistiocytosis [56–58]. These characteristics  
122 allowed the correct classification of 82.1% of the cases.

123 Cases misclassified totaling 10.93% of cases and are presented in Table 3:

124

125

Table 1. Misclassified cases


| WBC ( $10^9/L$ ) | Lymphocyte ( $10^9/L$ ) | Actual    | Predicted   |
|------------------|-------------------------|-----------|-------------|
| 5.6              | 2.2                     | Covid -19 | Arboviruses |
| 8.24             | 2.46                    | Covid -19 | Arboviruses |
| 6.48             | 1.98                    | Covid -19 | Arboviruses |
| 4.2              | 0.7                     | Covid -19 | Arboviruses |
| 4.23             | 1.28                    | Covid -19 | Arboviruses |
| 6.5              | 2.8                     | Covid -19 | Arboviruses |
| 11.4             | 2.7                     | Covid -19 | Arboviruses |

|      |      |             |             |
|------|------|-------------|-------------|
| 7.63 | 2.83 | Covid -19   | Arboviruses |
| 4.4  | 1.08 | Covid -19   | Arboviruses |
| 4.4  | 1.7  | Covid -19   | Arboviruses |
| 4.3  | 1.2  | Covid -19   | Arboviruses |
| 4.5  | 1.4  | Covid -19   | Arboviruses |
| 7.56 | 2.12 | Arboviruses | Covid -19   |
| 9.6  | 1.3  | Arboviruses | Covid -19   |
| 7.54 | 1.66 | Arboviruses | Covid -19   |
| 6.3  | 1.84 | Arboviruses | Covid -19   |
| 6.1  | 1    | Arboviruses | Covid -19   |
| 4.28 | 0.39 | Arboviruses | Covid -19   |
| 5.86 | 1.76 | Arboviruses | Covid -19   |
| 9.7  | 1.9  | Arboviruses | Covid -19   |

126

127 From the analysis of table 3 and figure 2, we can find the factors that allow the erroneous  
128 classification of patients: half of the patients affected by Covid-19 who have WBC values  
129 ( $\cong 5$ ) associated with low values of lymphocytes ( $> 2$ ) are classified as having  
130 arboviruses; while the other half is classified according to the high value of lymphocytes  
131 Patients affected by arboviruses who have lymphocytopenia (lymphocytes  $\leq 2$ ) and  
132 without leukopenia are classified as having Covid-19.

133



134

135 Figure 2. WBC x Lymphocyte count plot for patients classified incorrectly. The caption of each patient  
136 indicates the disease to which it is affected, the symbols indicate the predicted illness

137

#### 138 4 Conclusion

139

140 The model developed was effective in discriminating based on clinical data between  
141 patients affected by Covid-19 and patients affected by arboviruses (DENV, ZIKV,  
142 CHIKV), being able to predict 93.1% of the cases of SARS-CoV-2 and 82.1% of cases  
143 of arboviruses. Even though it presented a not very satisfactory result for arboviruses, the  
144 model allows the screening of patients with Coronavirus (contagious), thus speeding up  
145 the isolation and hospitalization procedures.

146 Because it was developed using free software, this model can be used in public health  
147 systems in countries in the event of a simultaneous outbreak of arboviruses and Covid-  
148 19, minimizing the impacts of a possible collapse of the health system.

149

#### 150 Acknowledgements



151

152 The author thanks the collaboration of doctors Marjorie Lobo and Tainá Cajazeira and  
153 the researcher Luane Barbosa for the review of this work.

154

155 References

156

157 [1] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X.  
158 Gu, Clinical features of patients infected with 2019 novel coronavirus in Wuhan ,  
159 China, *Lancet*. (2020) 497–506. doi:10.1016/S0140-6736(20)30183-5.

160 [2] World Health Organization, Coronavirus disease 2019 (COVID-19) Situation  
161 Report – 76, 2019 (2020). [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200405-sitrep-76-covid-19.pdf?sfvrsn=6ecf0977_4)  
162 [source/coronaviruse/situation-reports/20200405-sitrep-76-covid-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200405-sitrep-76-covid-19.pdf?sfvrsn=6ecf0977_4)  
163 [19.pdf?sfvrsn=6ecf0977\\_4](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200405-sitrep-76-covid-19.pdf?sfvrsn=6ecf0977_4).

164 [3] E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track  
165 COVID-19 in real time, *Lancet Infect. Dis.* 3099 (2020) 19–20.  
166 doi:10.1016/S1473-3099(20)30120-1.

167 [4] W. Guan, Z. Ni, Y. Hu, W. Liang, C. Ou, J. He, L. Liu, H. Shan, C. Lei, D.S.C.  
168 Hui, B. Du, L. Li, G. Zeng, K. Yuen, R. Chen, C. Tang, T. Wang, P. Chen, J.  
169 Xiang, S. Li, J. Wang, Z. Liang, Y. Peng, L. Wei, Y. Liu, Y. Hu, P. Peng, J.  
170 Wang, J. Liu, Z. Chen, G. Li, Z. Zheng, S. Qiu, J. Luo, C. Ye, S. Zhu, Clinical  
171 Characteristics of Coronavirus Disease 2019 in China, *N. Engl. J. Med.* (2020) 1–  
172 13. doi:10.1056/NEJMoa2002032.

173 [5] F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, J. Xiang, Y. Wang, B. Song, X.  
174 Gu, L. Guan, Y. Wei, Clinical course and risk factors for mortality of adult  
175 inpatients with COVID-19 in Wuhan , China : a retrospective cohort study,  
176 *Lancet*. 395 (2020) 1054–1062. doi:10.1016/S0140-6736(20)30566-3.

177 [6] A. Wilder-smith, D.J. Gubler, S.C. Weaver, T.P. Monath, D.L. Heymann, T.W.  
178 Scott, Epidemic arboviral diseases : priorities for research and public health,  
179 *Lancet Infect. Dis.* 3099 (2016) 1–6. doi:10.1016/S1473-3099(16)30518-7.

- 180 [7] A.P.B. Von Zuben, Maria Rita Donalisio, André Ricardo Ribas Freitas,  
181 Arboviroses emergentes no Brasil : desafios para a clínica e implicações para a  
182 saúde pública, *Rev. Saude Publica.* 51 (2017) 10–15.
- 183 [8] D. Musso, A.J. Rodriguez-morales, J.E. Levi, D.J. Gubler, Personal View  
184 Unexpected outbreaks of arbovirus infections : lessons learned from the Pacific  
185 and tropical America, *Lancet Infect. Dis.* 3099 (2018) 1–7. doi:10.1016/S1473-  
186 3099(18)30269-X.
- 187 [9] A.J. Rodriguez-Morales, V. Gallego, J.P. Escalera-Antezana, C.A. Méndez, L.I.  
188 Zambrano, C. Franco-Paredes, J.A. Suárez, H.D. Rodriguez-Enciso, G.J. Balbin-  
189 Ramon, E. Savio-Larriera, A. Risquez, S. Cimerman, COVID-19 in Latin  
190 America: The implications of the first confirmed case in Brazil, *Travel Med.*  
191 *Infect. Dis.* (2020) 101613. doi:10.1016/j.tmaid.2020.101613.
- 192 [10] M. Saavedra-Velasco, C. Chiara-Chilet, R. Pichardo-Rodriguez, A. Grandez-  
193 Urbina, F. Inga-Berrosipi, Coinfección entre dengue y COVID-19: Necesidad de  
194 abordaje en zonas endémicas, *Rev. Fac. Cienc. Med. Cordoba.* 77 (2020) 52–54.  
195 doi:10.31053/1853.0605.v77.n1.28031.
- 196 [11] J. Navarro, J. Arrivillaga-henríquez, J. Salazar-loor, A.J. Rodriguez-morales,  
197 COVID-19 and dengue, co-epidemics in Ecuador and other countries in Latin  
198 America: Pushing strained health care systems over the edge, *Travel Med. Infect.*  
199 *Dis.* (2020) 101656. doi:10.1016/j.tmaid.2020.101656.
- 200 [12] G. Yan, C.K. Lee, L.T.M. Lam, B. Yan, Y.X. Chua, A.Y.N. Lim, K.F. Phang, G.  
201 Sen Kew, H. Teng, C.H. Ngai, L. Lin, R.M. Foo, S. Pada, L.C. Ng, P.A.  
202 Tambyah, Covert COVID-19 and false-positive dengue serology in Singapore,  
203 *Lancet Infect. Dis.* 3099 (2020) 30158. doi:10.1016/S1473-3099(20)30158-4.
- 204 [13] B. joob, V. Wiwanitkit, COVID-19 can present with a rash and be mistaken for  
205 Dengue, *J. Am. Acad. Dermatol.* (2020) 19–22. doi:10.1016/j.jaad.2020.03.036.
- 206 [14] Y. Li, B. Liu, J. Cui, Z. Wang, Y. Shen, Y. Xu, K. Yao, Y. Guan, Similarities and  
207 Evolutionary Relationships of COVID-19 and Related Viruses, (2020).  
208 <http://arxiv.org/abs/2003.05580>.
- 209 [15] V.I. Avelino-Silva, J.F. Ramos, Arboviroses e políticas públicas no Brasil  
210 Arboviruses and public policies in Brazil, *Rev. Ciências Em Saúde.* 7 (2017) 1–2.

- 211           doi:10.21876/rcsfmit.v7i3.675.
- 212   [16]   Brasil, Monitoramento dos casos de arboviroses urbanas transmitidas pelo Aedes  
213           Aegypti (dengue, chikungunya e zika), Semanas Epidemiológicas 1 a 13, 2020,  
214           Bol. Epidemiológico 14. 51 (2020) 1–34.  
215           [https://www.saude.gov.br/images/pdf/2020/April/03/Boletim-epidemiologico-](https://www.saude.gov.br/images/pdf/2020/April/03/Boletim-epidemiologico-SVS-14.pdf)  
216           SVS-14.pdf.
- 217   [17]   Brasil, Doença pelo Coronavírus 2019, Bol. Epidemiológico Do Cent. Operações  
218           Emergência Em Saúde Pública 06. 06 (2020) 1–23.  
219           [https://portalarquivos.saude.gov.br/images/pdf/2020/April/03/BE6-Boletim-](https://portalarquivos.saude.gov.br/images/pdf/2020/April/03/BE6-Boletim-Especial-do-COE.pdf)  
220           Especial-do-COE.pdf.
- 221   [18]   G. Lippi, M. Plebani, B. Michael, Thrombocytopenia is associated with severe  
222           coronavirus disease 2019 ( COVID-19 ) infections : A meta -analysis, Clin.  
223           Chim. Acta. 506 (2020) 145–148. doi:10.1016/j.cca.2020.03.022.
- 224   [19]   T. Elias, C. Fernanda, A. Francesli, N. Reis, N. Santos, M. Lima, E. Márcia, S.  
225           Cabrera, I. Nuremberg, F. Rodrigues, L. Elisa, A. Antônio, Clinical , laboratory  
226           and virological data from suspected ZIKV patients in an endemic arbovirus area,  
227           J. Clin. Virol. 96 (2017) 20–25. doi:10.1016/j.jcv.2017.09.002.
- 228   [20]   M. Kapdi, I.R.A. Shah, Dengue and haemophagocytic lymphohistiocytosis,  
229           Scand. J. Infect. Dis. (2012) 708–709. doi:10.3109/00365548.2011.652667.
- 230   [21]   S.-C.J. Wæhre T, Maagard A, Tappe D, Cadar D, Zika Virus Infection after  
231           Travel to Tahiti , December 2013, Emerg. Infect. Dis. 20 (2014) 8–10.
- 232   [22]   L. Dupuis-Maguiraga, M. Noret, S. Brun, R. Le Grand, G. Gras, P. Roques,  
233           Chikungunya Disease : Infection-Associated Markers from the Acute to the  
234           Chronic Phase of Arbovirus-Induced Arthralgia, PLoS Negl. Trop. Dis. 6 (2012).  
235           doi:10.1371/journal.pntd.0001446.
- 236   [23]   E. Data4u, Diagnosis of COVID-19 and its clinical spectrum, Kaggle. (2020).  
237           <https://www.kaggle.com/einsteindata4u/covid19> (accessed April 5, 2020).
- 238   [24]   J. Demsar, B. Zupan, G. Leban, T. Curk, Orange : From Experimental Machine  
239           Learning, Knowl. Discov. Databases PKDD 2004. (2004) 537–539.  
240           doi:10.1007/978-3-540-30116-5\_58.

- 241 [25] J. Luts, F. Ojeda, R. Van de Plas Raf, B. De Moor, S. Van Huffel, J.A.K.  
242 Suykens, A tutorial on support vector machine-based methods for classification  
243 problems in chemometrics, *Anal. Chim. Acta.* 665 (2010) 129–145.  
244 doi:10.1016/j.aca.2010.03.030.
- 245 [26] H. Chen, J. Guo, C. Wang, F. Luo, X. Yu, W. Zhang, J. Li, D. Zhao, D. Xu, Q.  
246 Gong, J. Liao, H. Yang, W. Hou, Y. Zhang, Clinical characteristics and  
247 intrauterine vertical transmission potential of COVID-19 infection in nine  
248 pregnant women: a retrospective review of medical records, *Lancet.* 395 (2020)  
249 809–815. doi:10.1016/S0140-6736(20)30360-3.
- 250 [27] R. Wang, C. Liao, H. He, C. Hu, Z. Wei, Z. Hong, C. Zhang, M. Liao, H. Shui,  
251 COVID-19 in Hemodialysis Patients: A Report of 5 Cases, *Am. J. Kidney Dis.*  
252 (2020). doi:10.1053/j.ajkd.2020.03.009.
- 253 [28] F. Ye, S. Xu, Z. Rong, R. Xu, X. Liu, P. Deng, H. Liu, X. Xu, Delivery of  
254 infection from asymptomatic carriers of COVID-19 in a familial cluster, *Int. J.*  
255 *Infect. Dis.* 105 (2020) 72–80. doi:10.1016/j.ijid.2020.03.042.
- 256 [29] G. Ye, Z. Pan, Y. Pan, Q. Deng, L. Chen, J. Li, Y. Li, X. Wang, Clinical  
257 characteristics of severe acute respiratory syndrome coronavirus 2 reactivation, *J.*  
258 *Infect.* (2020) 3–6. doi:10.1016/j.jinf.2020.03.001.
- 259 [30] J.F.W. Chan, S. Yuan, K.H. Kok, K.K.W. To, H. Chu, J. Yang, F. Xing, J. Liu,  
260 C.C.Y. Yip, R.W.S. Poon, H.W. Tsoi, S.K.F. Lo, K.H. Chan, V.K.M. Poon,  
261 W.M. Chan, J.D. Ip, J.P. Cai, V.C.C. Cheng, H. Chen, C.K.M. Hui, K.Y. Yuen,  
262 A familial cluster of pneumonia associated with the 2019 novel coronavirus  
263 indicating person-to-person transmission: a study of a family cluster, *Lancet.* 395  
264 (2020) 514–523. doi:10.1016/S0140-6736(20)30154-9.
- 265 [31] Z. Wang, X. Chen, Y. Lu, F. Chen, W. Zhang, Clinical characteristics and  
266 therapeutic procedure for four cases with 2019 novel coronavirus pneumonia  
267 receiving combined Chinese and Western medicine treatment, *Biosci. Trends.* 14  
268 (2020) 64–68. doi:10.5582/bst.2020.01030.
- 269 [32] P. Yu, J. Zhu, Z. Zhang, Y. Han, L. Huang, A familial cluster of infection  
270 associated with the 2019 novel coronavirus indicating potential person-to-person  
271 transmission during the incubation period, *J. Infect. Dis.* (2020) 1–5.

- 272 doi:10.1093/infdis/jiaa077.
- 273 [33] X. Wang, Z. Zhou, J. Zhang, F. Zhu, Y. Tang, X. Shen, A case of 2019 Novel  
274 Coronavirus in a pregnant woman with preterm delivery, *Clin. Infect. Dis.*  
275 (2020). doi:10.1093/cid/ciaa200.
- 276 [34] Y. Wu, X. Cui, N. Wu, R. Song, W. Yang, W. Zhang, D. Fan, Z. Chen, J. An, A  
277 unique case of human Zika virus infection in association with severe liver injury  
278 and coagulation disorders, *Sci. Rep.* 7 (2017) 1–8. doi:10.1038/s41598-017-  
279 11568-4.
- 280 [35] G.H.Y. Leung, R.W. Baird, J. Druce, N.M. Anstey, Zika virus infection in  
281 Australia following a monkey bite in Indonesia, *Southeast Asian J. Trop. Med.*  
282 *Public Health.* 46 (2015) 460–464.
- 283 [36] H.C. Jang, W.B. Park, U.J. Kim, J.Y. Chun, S.J. Choi, P.G. Choe, S.I. Jung, Y.  
284 Jee, N.J. Kim, E.H. Choi, M.D. Oh, First imported case of Zika virus infection  
285 into Korea, *J. Korean Med. Sci.* 31 (2016) 1173–1177.  
286 doi:10.3346/jkms.2016.31.7.1173.
- 287 [37] J. Li, C.Y. Chong, N.W. Tan, C.F. Yung, N.W. Tee, K.C. Thoon, Characteristics  
288 of Zika Virus Disease in Children: Clinical, Hematological, and Virological  
289 Findings from an Outbreak in Singapore, *Clin. Infect. Dis.* 64 (2017) 1445–1448.  
290 doi:10.1093/cid/cix137.
- 291 [38] L.H. Chen, Zika Virus Infection in a Massachusetts Resident After Travel to  
292 Costa Rica: A Case Report, *Ann. Intern. Med.* 164 (2016) 574. doi:10.7326/L16-  
293 0075.
- 294 [39] A.F. Cardona-Cardona, A.J. Rodríguez Morales, Severe abdominal pain in a  
295 patient with Zika infection: A case in Risaralda, Colombia, *J. Infect. Public*  
296 *Health.* 9 (2016) 372–373. doi:10.1016/j.jiph.2016.03.001.
- 297 [40] C. Therrien, G. Jourdan, K. Holloway, C. Tremblay, M.A. Drebot, First Imported  
298 Case of Chikungunya Virus Infection in a Travelling Canadian Returning from  
299 the Caribbean, *Can. J. Infect. Dis. Med. Microbiol.* 2016 (2016).  
300 doi:10.1155/2016/2980297.
- 301 [41] G.M. Oliveira, T.M.A. Marques, J.R. Dos Santos, E.D.F. Daher, R.D. Leite, E.S.

- 302 Girão, R. da J.P. Neto, Clinical and laboratory profiles of children with sever  
303 chikungunya infection, *Rev. Soc. Bras. Med. Trop.* 52 (2019) 2017–2020.  
304 doi:10.1590/0037-8682-0232-2018.
- 305 [42] M.M. Aly, S. Ali, A.F. Muianga, V. Monteiro, J.G. Gallego, J. Weyer, K.I. Falk,  
306 J.T. Paweska, J. Cliff, E.S. Gudo, Severe Chikungunya infection in Northern  
307 Mozambique: a case report, *BMC Res. Notes.* 10 (2017) 4–9.  
308 doi:10.1186/s13104-017-2417-z.
- 309 [43] M.C. Schechter, K.A. Workowski, J.K. Fairley, Unusual Presentation of  
310 Chikungunya Virus Infection With Concomitant Erysipelas in a Returning  
311 Traveler From the Caribbean: A Case Report, *Open Forum Infect. Dis.* 1 (2014)  
312 ofu097–ofu097. doi:10.1093/ofid/ofu097.
- 313 [44] J.M. de la Hoz, B. Bayona, S. Viloría, J.L. Accini, H.S. Juan-Vergara, D. Viasus,  
314 Fatal cases of Chikungunya virus infection in Colombia: Diagnostic and  
315 treatment challenges, *J. Clin. Virol.* 69 (2015) 27–29.  
316 doi:10.1016/j.jcv.2015.05.021.
- 317 [45] I. Eckerle, V.T. Briciu, Ergönül, M. Lupş, A. Papa, A. Radulescu, S. Tsiodras,  
318 C. Tsiou, C. Drosten, V.R. Nussenblatt, C.B. Reusken, L.A. Sigfrid, N.J.  
319 Beeching, Emerging souvenirs—clinical presentation of the returning traveller  
320 with imported arbovirus infections in Europe, *Clin. Microbiol. Infect.* 24 (2018)  
321 240–245. doi:10.1016/j.cmi.2018.01.007.
- 322 [46] P.Y. Chia, H. Sen Yew, H. Ho, A. Chow, S.P. Sadarangani, M. Chan, Y.W. Kam,  
323 C.Y. Chong, K.C. Thoon, C.F. Yung, J.H. Li, D.C. Lye, P.P. De, L.F.P. Ng, T.W.  
324 Yeo, Y.S. Leo, Clinical features of patients with Zika and dengue virus co-  
325 infection in Singapore, *J. Infect.* 74 (2017) 611–615.  
326 doi:10.1016/j.jinf.2017.03.007.
- 327 [47] M. Mardani, F. Abbasi, M. Aghahasani, B. Ghavam, First Iranian imported case  
328 of dengue, *Int. J. Prev. Med.* 4 (2013) 1075–1077.
- 329 [48] S. Advani, S. Agarwal, J. Verma, Haemogram profile of dengue fever in adults  
330 during 19 September – 12 November 2008: A study of 40 cases from Delhi.,  
331 *Dengue Bull.* 35 (2011) 71–75. <https://apps.who.int/iris/handle/10665/171014>.
- 332 [49] D. Ballabio, F. Grisoni, R. Todeschini, Multivariate comparison of classification

- 333 performance measures, *Chemom. Intell. Lab. Syst.* 174 (2018) 33–44.  
334 doi:10.1016/j.chemolab.2017.12.004.
- 335 [50] L. Zeng, S. Xia, W. Yuan, K. Yan, F. Xiao, J. Shao, W. Zhou, Neonatal Early-  
336 Onset Infection with SARS-CoV-2 in 33 Neonates Born to Mothers with  
337 COVID-19 in Wuhan, China, *JAMA Pediatr.* 23 (2020) 4–6.  
338 doi:10.1001/jamapediatrics.2020.0878.
- 339 [51] X. Yang, Y. Yu, J. Xu, H. Shu, J. Xia, H. Liu, Y. Wu, L. Zhang, Z. Yu, M. Fang,  
340 T. Yu, Y. Wang, S. Pan, X. Zou, S. Yuan, Y. Shang, Clinical course and  
341 outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,  
342 China: a single-centered, retrospective, observational study, *Lancet Respir. Med.*  
343 2600 (2020) 1–7. doi:10.1016/S2213-2600(20)30079-5.
- 344 [52] D. Wu, T. Wu, Q. Liu, Z. Yang, The SARS-CoV-2 outbreak: what we know., *Int.*  
345 *J. Infect. Dis.* (2020). doi:10.1016/j.ijid.2020.03.004.
- 346 [53] Pan American Health Organization (PAHO), Tool for the diagnosis and care of  
347 patients with suspected arboviral diseases, 2017.  
348 <http://iris.paho.org/xmlui/handle/123456789/33895>.
- 349 [54] E.L. Azeredo, F.B. dos Santos, L.S. Barbosa, T.M.A. Souza, J. Badolato-Corrêa,  
350 J.C. Sánchez-Arcila, P.C.G. Nunes, L.M. de-Oliveira-Pinto, A.M. de Filippis, M.  
351 Dal Fabbro, I. Hoscher Romanholi, R. Cunha, Clinical and Laboratory Profile of  
352 Zika and Dengue Infected Patients: Lessons Learned From the Co-circulation of  
353 Dengue, Zika and Chikungunya in Brazil, *PLoS Curr.* (2018) 1–20.  
354 doi:10.1371/currents.outbreaks.0bf6aeb4d30824de63c4d5d745b217f5.
- 355 [55] R. Li, J. Ding, G. Ding, X. Fan, Y. He, X. Wang, H. Zhang, J. Ji, H. Li, Zika  
356 virus infections, a review, *Radiol. Infect. Dis.* 4 (2017) 88–93.  
357 doi:10.1016/j.jrid.2017.01.002.
- 358 [56] S.L. Beltrán-Silva, S.S. Chacón-Hernández, E. Moreno-Palacios, J.Á. Pereyra-  
359 Molina, Clinical and differential diagnosis: Dengue, chikungunya and Zika, *Rev.*  
360 *Médica Del Hosp. Gen. México.* 81 (2018) 146–153.  
361 doi:10.1016/j.hgmx.2016.09.011.
- 362 [57] E.M. Ellis, T.M. Sharp, J. Pérez-Padilla, L. González, B.K. Poole-Smith, E.  
363 Lebo, C. Baker, M.J. Delorey, B. Torres-Velasquez, E. Ochoa, B. Rivera-Garcia,

- 364 H. Díaz-Pinto, L. Clavell, A. Puig-Ramos, G.E. Janka, K.M. Tomashek,  
365 Incidence and Risk Factors for Developing Dengue-Associated Hemophagocytic  
366 Lymphohistiocytosis in Puerto Rico, 2008 - 2013, PLoS Negl. Trop. Dis. 10  
367 (2016) 2008–2013. doi:10.1371/journal.pntd.0004939.
- 368 [58] T.M. Sharp, L. Gaul, A. Muehlenbachs, E. Hunsperger, J. Bhatnagar, R.  
369 Lueptow, G.A. Santiago, J.L. Muñoz-Jordan, D.M. Blau, P. Ettestad, J.D. Bissett,  
370 S.C. Ledet, S.R. Zaki, K.M. Tomashek, Fatal hemophagocytic  
371 lymphohistiocytosis associated with locally acquired dengue virus infection -  
372 New Mexico and Texas, 2012, Morb. Mortal. Wkly. Rep. 63 (2014) 49–54.  
373 doi:10.1016/j.annemergmed.2014.04.007.
- 374
- 375